ATC code A
Source: Wikipedia, the free encyclopedia.
Pharmaceutical drug classification
ATC code A: Alimentary tract and metabolism |
---|
|
Other ATC codes |
ATC code A Alimentary tract and metabolism is a section of the
Codes for
ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QA.[5]
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
References
- ^ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- ^ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- ^ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- ^ "ATC/DDD Index 2022: code A". WHO Collaborating Centre for Drug Statistics Methodology.
- ^ "ATCvet Index 2022: code QA". WHO Collaborating Centre for Drug Statistics Methodology.
Magnesium (increases motility) | |
---|---|
Aluminium (decreases motility) |
|
Calcium | |
Sodium | |
Combinations and complexes of aluminium, calcium and magnesium |
| ||
---|---|---|
Prostaglandins (E)/ analogues ("-prost-") | ||
Proton-pump inhibitors ("-prazole") | ||
Potassium-competitive ("-prazan")acid blockers | ||
Others | ||
Combinations | ||
|
Drugs for functional gastrointestinal disorders (A03) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drugs for functional bowel disorders |
| ||||||||||||
Belladonna and derivatives (antimuscarinics) |
| ||||||||||||
Propulsives |
5-HT3 serotonin ion channel antagonists | |
---|---|
5-HT serotonin G-protein receptor antagonists | |
) | |
D2/D3 antagonists | |
antihistamines ) | |
antagonists )(anticholinergics |
|
NK1 antagonists | |
Others |
Bile and liver therapy (A05) | |
---|---|
Bile therapy | |
Liver therapy |
|
| ||
---|---|---|
Stimulant laxatives | ||
Bulk-forming laxatives | ||
Lubricant laxatives | ||
Osmotic laxatives | ||
Enemas | ||
Opioid antagonists | ||
Others |
| |
---|---|
Rehydration | |
Intestinal anti-infectives |
|
Intestinal adsorbents |
|
Antipropulsives (opioids) |
|
Intestinal anti-inflammatory agents |
|
Antidiarrheal micro-organisms | |
Other antidiarrheals | |
|
antagonists
receptor agonists
- Beloranib§
- Bimagrumab§
- Desiccated thyroid‡
- Metformin
- Metreleptin
- Naltrexone
- Setmelanotide
- Topiramate
- ZGN-1061
- Zonisamide
- Water
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
Fat soluble |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Water soluble |
| ||||||||
Combinations | |||||||||
|
Major |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trace |
| ||||||||||||
Ultratrace |
| ||||||||||||
|
|
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Antiandrogens |
| ||||||||||||
|
| |
---|---|
Exogenous | |
Endogenous |
| |
---|---|
Amino acids and derivatives |
|
Enzymes |
|
Other |